{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T12:20:49Z","timestamp":1666009249746},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T00:00:00Z","timestamp":1341964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s00393-011-0880-9","type":"journal-article","created":{"date-parts":[[2012,7,9]],"date-time":"2012-07-09T03:55:15Z","timestamp":1341806115000},"page":"479-484","source":"Crossref","is-referenced-by-count":2,"title":["Neue Kinasehemmer"],"prefix":"10.1007","volume":"71","author":[{"given":"A.","family":"Rubbert-Roth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,11]]},"reference":[{"key":"880_CR1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1517\/13543784.17.5.641","volume":"17","author":"Bajpai","year":"2008","unstructured":"Bajpai M, Chopra P, Dastidar SG et al (2008) Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis. Expert Opin Investig Drugs 17:641","journal-title":"Expert Opin Investig Drugs"},{"key":"880_CR2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1124\/jpet.105.097436","volume":"317","author":"Cha","year":"2006","unstructured":"Cha HS, Boyle DS, Inoue T et al (2006) A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 317:571\u2013578","journal-title":"J Pharmacol Exp Ther"},{"key":"880_CR3","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar3400","volume":"13","author":"Chang","year":"2011","unstructured":"Chang BY, Huang MM, Francesco M et al (2011) The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 13(4):R115","journal-title":"Arthritis Res Ther"},{"key":"880_CR4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/art.24266","volume":"60","author":"Cohen","year":"2009","unstructured":"Cohen SB, Cheng TT, Chindalore V et al (2009) Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 60(2):335\u2013344","journal-title":"Arthritis Rheum"},{"key":"880_CR5","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/art.24485","volume":"60","author":"Damjanov","year":"2009","unstructured":"Damjanov N, Kauffman RS, Spencer-Green GT (2009) Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 60(5):1232\u20131241","journal-title":"Arthritis Rheum"},{"key":"880_CR6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1189\/jlb.1110640","volume":"90","author":"Dehlin","year":"2011","unstructured":"Dehlin M, Andersson S, Erlandsson M et al (2011) Inhibition of fms-like tyrosine kinase three alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation. J Leukoc Biol 90(4):811\u2013817","journal-title":"J Leukoc Biol"},{"key":"880_CR7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/art.24264","volume":"60","author":"Genovese","year":"2009","unstructured":"Genovese MC (2009) Inhibition of p38: Has the fat lady sung? Arthritis Rheum 60(2):317\u2013320","journal-title":"Arthritis Rheum"},{"key":"880_CR8","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/art.27325","volume":"62","author":"Genovese","year":"2010","unstructured":"Genovese MC, Gao L, Yin J et al (2010) Proof of concept study for a potent p38 MAPK dual action inhibitor BMS 582949 in subjects with RA receiving concomitant methotrexate. Arthritis Rheum 62(Suppl 10):1119","journal-title":"Arthritis Rheum"},{"key":"880_CR9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/art.30114","volume":"63","author":"Genovese","year":"2011","unstructured":"Genovese MC, Kavanaugh A, Weinblatt ME et al (2011) An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 63:337\u2013345","journal-title":"Arthritis Rheum"},{"key":"880_CR10","doi-asserted-by":"crossref","first-page":"842181","DOI":"10.1155\/2011\/842181","volume":"2011","author":"Gordon","year":"2011","unstructured":"Gordon J, Spiera R (2011) Tyrosine kinase inhibitors in the treatment of systemic sclerosis: the difficulty in interpreting proof-of concept studies. Int J Rheumatol 2011:842181","journal-title":"Int J Rheumatol"},{"key":"880_CR11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/ard.2009.119479","volume":"69","author":"Hammaker","year":"2010","unstructured":"Hammaker D, Firestein GS (2010) \u201eGo Upstream, young man\u201c lessons learnt from the p38 saga. Ann Rheum Dis 69(Suppl 1):77\u201382","journal-title":"Ann Rheum Dis"},{"key":"880_CR12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1172\/JCI12466","volume":"108","author":"Han","year":"2001","unstructured":"Han Z, Boyle DL, Chan L et al (2001) C-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 108:73\u201381","journal-title":"J Clin Invest"},{"key":"880_CR13","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","volume":"104","author":"Hantschel","year":"2007","unstructured":"Hantschel O, Rix U, Schmidt U et al (2007) The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 104(33):13283\u201313288","journal-title":"Proc Natl Acad Sci U S A"},{"key":"880_CR14","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1002\/art.22080","volume":"54","author":"Korb","year":"2006","unstructured":"Korb A, Tohidast-Akrad M, Cetin E et al (2006) Differential tissue expression and activation of p38 MAPK \u03b1, \u03b2, \u03b3 and \u03b4 isoforms in rheumatoid arthritis. Arthritis Rheum 54:2745\u20132756","journal-title":"Arthritis Rheum"},{"key":"880_CR15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s10165-007-0592-9","volume":"17","author":"Koyama","year":"2007","unstructured":"Koyama K, Hatsushika K, Ando T et al (2007) Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice. Mod Rheumatol 17(4):306\u2013310","journal-title":"Mod Rheumatol"},{"key":"880_CR16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-065X.2008.00748.x","volume":"228","author":"Kurosaki","year":"2009","unstructured":"Kurosaki T, Hikida M (2009) Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev 228:132\u2013148","journal-title":"Immunol Rev"},{"key":"880_CR17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","volume":"228","author":"Mohamed","year":"2009","unstructured":"Mohamed AJ, Yu L, B\u00e4ckesj\u00f6 CM et al (2009) Bruton\u2019s tyrosine kinase (Btk): function, regulation, and transformation with spezial emphasis on the PH domain. Immunol Rev 228:58\u201372","journal-title":"Immunol Rev"},{"key":"880_CR18","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1002\/eji.200323810","volume":"33","author":"Nandakumar","year":"2003","unstructured":"Nandakumar KS, Andren M, Martinsson P et al (2003) Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory Fcgamma RIIB. Eur J Immunol 33(8):2269\u20132277","journal-title":"Eur J Immunol"},{"key":"880_CR19","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1002\/art.11227","volume":"48","author":"Nishikawa","year":"2003","unstructured":"Nishikawa M, Myoui A, Tomita T et al (2003) Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR 167653. Arthritis Rheum 48(9):2670\u20132681","journal-title":"Arthritis Rheum"},{"key":"880_CR20","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1172\/JCI28546.","volume":"116","author":"Paniagua","year":"2006","unstructured":"Paniagua RT, Sharpe O, Ho PP et al (2006) Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 116(10):2633\u20132642","journal-title":"J Clin Invest"},{"key":"880_CR21","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jbspin.2010.03.014","volume":"77","author":"Pereira","year":"2010","unstructured":"Pereira I, Fialho S, Castro G et al (2010) Imatinib mesylate induces clinical remission in rheumatoid arthritis. Joint Bone Spine 77(4):372\u2013373","journal-title":"Joint Bone Spine"},{"key":"880_CR22","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2010.143974","volume":"70","author":"Spiera","year":"2011","unstructured":"Spiera RF, Gordon JK, Mersten JN et al (2011) Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 70(6):1003\u20131009","journal-title":"Ann Rheum Dis"},{"key":"880_CR23","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar2740","volume":"Ther11","author":"Tebib","year":"2009","unstructured":"Tebib J, Mariette X, Bourgeois P et al (2009) Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther11:R95","journal-title":"Arthritis Res"},{"key":"880_CR24","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s10165-009-0193-x","volume":"19","author":"Terabe","year":"2009","unstructured":"Terabe F, Kitano M, Kawai M et al (2009) Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway. Mod Rheumatol 19(5):522\u2013529","journal-title":"Mod Rheumatol"},{"key":"880_CR25","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1002\/art.22869","volume":"56","author":"Thiel","year":"2007","unstructured":"Thiel MJ, Schaefer CJ, Lesch ME et al (2007) Central role of the MEK\/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms. Arthritis Rheum 56:3347\u20133357","journal-title":"Arthritis Rheum"},{"key":"880_CR26","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1002\/art.23992","volume":"58","author":"Weinblatt","year":"2008","unstructured":"Weinblatt ME, Kavanaugh A, Burgos-Vargas R et al (2008) Treatment of rheumatoid arthritis with a Syk kinase inhibitor \u2013 a twelve-week randomized, placebo-controlled trial. Arthritis Rheum 58:3309\u20133318","journal-title":"Arthritis Rheum"},{"key":"880_CR27","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1000500","volume":"363","author":"Weinblatt","year":"2010","unstructured":"Weinblatt ME, Kavanaugh A, Genovese MC et al (2010) An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 363(14):1303\u20131312","journal-title":"N Engl J Med"},{"key":"880_CR28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/art.21626","volume":"54","author":"Zwerina","year":"2006","unstructured":"Zwerina J, Hayer S, Redlich K et al (2006) Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 54(2):463\u2013472","journal-title":"Arthritis Rheum"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-011-0880-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-011-0880-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-011-0880-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T12:36:08Z","timestamp":1559046968000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-011-0880-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["880"],"URL":"https:\/\/doi.org\/10.1007\/s00393-011-0880-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,11]]}}}